Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission has allowed Nycomed to market its cancer breakthrough pain (BTP) treatment Instanyl single-dose nasal spray in European nations.
Subscribe to our email newsletter
Following EC’s approval, the company is now set to launch the spray in September 2011.
Developed by Nycomed, Instanyl fentanyl nasal spray will be launched in 50µg, 100µg, and 200µg strengths.
Norwegian University of Science and Technology professor Stein Kaasa said the launch of the single-dose nasal spray will ease the management of dose titration and modification, which together with the nasal spray’s safety and convenience should contribute to further improving the management of breakthrough pain.